Navigation Links
ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders
Date:9/6/2010

hase III clinical trials for the non-surgical treatment of retinal disorders. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (anti-Factor VIII), a long acting anti-coagulant in Phase II, and TB-403 (anti-PlGF) in Phase Ib/II for cancer in partnership with Roche.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

For further information please contact: ThromboGenics Dr. Steve Pakola, CMO Tel: +1-212-201-0920 steve.pakola@thrombogenics.com Dr. Patrik De Haes, CEO Tel: +32-16-75-13-10 patrik.dehaes@thrombogenics.com Citigate Dewe Rogerson Amber Bielecka/David Dible/Nina Enegren Tel: +44(0)207-638-95-71 amber.bielecka@citigatedr.co.uk
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
9. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
10. ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
11. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... SAN ANTONIO , Jan. 15, 2014 Most ... take, according to a recent online survey* sponsored by ... among the National Osteoporosis Foundation online support community, ... to take medication that comes in a form other ...
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and ... be able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of the ... steadfastly remains one of the most litigious industry ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Fla., April 20, 2011 Legal-Bay LLC, through its ... making a substantial commitment to plaintiffs in need of ... Cases.  Legal-Bay is already an industry leader; however they ... funding areas.  Recently the company announced that they have ...
... 2011 The Society of ... taking a leading role in measuring and assessing radiation ... and reduction of skin dosage; and promoting the safety ... this month in the Journal of Vascular and Interventional ...
Cached Medicine Technology:Legal-Bay LLC Announces Opening of Jones Act Lawsuit Funding Division 2Society of Interventional Radiology Addresses Radiation Safety, Advances Best Practices 2Society of Interventional Radiology Addresses Radiation Safety, Advances Best Practices 3Society of Interventional Radiology Addresses Radiation Safety, Advances Best Practices 4Society of Interventional Radiology Addresses Radiation Safety, Advances Best Practices 5
(Date:7/11/2014)... adults who screened positive for a history of hazardous ... than 50 percent after receiving mobile phone text messages ... a study published online yesterday in Annals of ... for Young Adult Emergency Department Patients: A Randomized Clinical ... than 50,000 adults ages 18 to 24 visit ERs ...
(Date:7/11/2014)... Recently, Fadhits.com, the distinguished wedding dress manufacturer and retailer, has ... To bring more benefits to worldwide clients in this great ... for these brand new items. Clients can enjoy thwe special ... says gladly, “We are happy to announce such a promotion. ... new and old customers and strengthen our relationship with them. ...
(Date:7/11/2014)... Hills, CA (PRWEB) July 11, 2014 Bedros ... marketing expert; a title he’s earned by founding the fast-selling ... professionals on marketing their businesses. He works with successful boot ... blog post on the traits of the most successful ... earners share three important qualities. , “I’ve worked with and ...
(Date:7/11/2014)... H.E.A.R Me Out Listens to Needs of Hearing ... provide comprehensive information and services available to Colorado’s hearing ... with hearing loss, this organization is the first of ... local and state resources that aims to give new ... Me Out and its website was founded by Colorado ...
(Date:7/11/2014)... is history in much of the world, but remains ... vaccinated children an extra dose of inactivated polio vaccine ... infectious disease, a new study suggests. Although the ... as a year after vaccination. Vaccinated children and adults ... of the disease, according to background information in the ...
Breaking Medicine News(10 mins):Health News:Text message medicine: Texts from the ER can reduce binge drinking 2Health News:Promotion for Kids Prom Dresses Now Provided at Fadhits.com 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 3Health News:H.E.A.R Me Out Listens to Needs of Hearing Impaired 2Health News:H.E.A.R Me Out Listens to Needs of Hearing Impaired 3Health News:Researchers Assess New Way to Boost Polio Immunity 2
... study has found that among women who have never ... increased risk of developing ovarian cancer compared with women ... issue of CANCER , a peer-reviewed journal of ... may contribute to the development of ovarian cancer through ...
... is urging women to continue waging a battle against the Food ... hormones. , ... Potomac, MD (PRWEB) January 2, 2009 ... health practitioner, is urging women to continue waging a battle against ...
... The National Parkinson Foundation (NPF) awarded ... new evidence-based interventions aimed at preventing falls in ... grants to five different research projects at NPF ... and the United States. NPF supports a ...
... asks you to help save lives by donating blood ... being held on Tuesday, January 6th from 2 pm ... Gloucester City, New Jersey. To make an immediate ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081216/DC52619LOGO ) Goldglantz suffered 3rd ...
... while performing winter task , , FRIDAY, Jan. 2 (HealthDay ... can be physically challenging and dangerous work, so you ... the American Academy of Orthopaedic Surgeons (AAOS). , ... U.S. hospital emergency rooms, doctors, offices, clinics and other ...
... key to understanding, and perhaps killing, dormant ovarian cancer ... years later, researchers at The University of Texas M. ... Journal of Clinical Investigation . , The team found ... a switch for autophagy, or self-cannibalization, in ovarian cancer ...
Cached Medicine News:Health News:Study links obesity to elevated risk of ovarian cancer 2Health News:Susan Lark, MD Urges Women to Fight for Their Right to Use Bioidentical Hormones 2Health News:Susan Lark, MD Urges Women to Fight for Their Right to Use Bioidentical Hormones 3Health News:The National Parkinson Foundation Awards Five Grants for the Falls Prevention Initiative 2Health News:The National Parkinson Foundation Awards Five Grants for the Falls Prevention Initiative 3Health News:Blood Drive Held in Honor of Gloucester City Resident - Evan Goldglantz 2Health News:Shovel Snow Safely 2Health News:Dormant cancer cells rely on cellular self-cannibalization to survive 2
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Inoculum Broth with Calcium Chloride and Phytone....
...
Medicine Products: